Notch-Dependent Repression of miR-155 in the Bone Marrow Niche Regulates Hematopoiesis in an NF-κB-Dependent Manner  by Wang, Lin et al.
Cell Stem Cell
ArticleNotch-Dependent Repression of miR-155
in the Bone Marrow Niche Regulates Hematopoiesis
in an NF-kB-Dependent Manner
Lin Wang,1 Huajia Zhang,1 Sonia Rodriguez,1 Liyun Cao,1 Jonathan Parish,1 Christen Mumaw,1 Amy Zollman,1
Malgorzata M. Kamoka,2 Jian Mu,3 Danny Z. Chen,3 Edward F. Srour,1,2 Brahmananda R. Chitteti,2 Harm HogenEsch,4
Xiaolin Tu,5 Teresita M. Bellido,5 H. Scott Boswell,2 Taghi Manshouri,6 Srdan Verstovsek,6 Mervin C. Yoder,1
Reuben Kapur,1 Angelo A. Cardoso,1 and Nadia Carlesso1,*
1Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
2Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
3Department of Computer Science and Engineering, University of Notre Dame, South Bend, IN 46556, USA
4Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA
5Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
6Leukemia Department, MD Anderson Cancer Center, Houston, TX 77030, USA
*Correspondence: ncarless@iu.edu
http://dx.doi.org/10.1016/j.stem.2014.04.021SUMMARY
The microRNA miR-155 has been implicated in regu-
lating inflammatory responses and tumorigenesis,
but its precise role in linking inflammation and cancer
has remained elusive. Here, we identify a connection
betweenmiR-155 and Notch signaling in this context.
Loss of Notch signaling in the bone marrow (BM)
niche alters hematopoietic homeostasis and leads
to lethal myeloproliferative-like disease. Mechanisti-
cally, Notch signaling represses miR-155 expression
by promoting binding of RBPJ to the miR-155 pro-
moter. Loss of Notch/RBPJ signaling upregulates
miR-155 in BM endothelial cells, leading to miR-155-
mediated targeting of the nuclear factor kB (NF-kB)
inhibitor kB-Ras1, NF-kB activation, and increased
proinflammatory cytokine production. Deletion of
miR-155 in the stroma of RBPJ/ mice prevented
the development of myeloproliferative-like disease
and cytokine induction. Analysis of BM from patients
carrying myeloproliferative neoplasia also revealed
elevated expression of miR-155. Thus, the Notch/
miR-155/kB-Ras1/NF-kB axis regulates the inflam-
matory state of the BMniche and affects the develop-
ment of myeloproliferative disorders.
INTRODUCTION
Notch signaling plays an essential role in regulating normal and
abnormal hematopoietic stem and progenitor cell development
and functions. Although Notch’s cell-autonomous role in this
process is well established, its non-cell-autonomous role re-
mains little understood. Specifically, the cellular and molecular
mechanism(s) by which Notch loss-of-function regulates the
integrity of the bone marrow (BM) niche is poorly defined.
Here, we used a conditional knockout model of RBPJ, a nonre-dundant downstream effector of the canonical Notch signaling
cascade, to determine the contribution of Notch signaling to
the non-cell-autonomous regulation of hematopoiesis.
Notch genes encode large, highly conserved type 1 trans-
membrane receptors, which are activated through cell-cell con-
tact by binding to one of their ligands on neighboring cells
(Artavanis-Tsakonas et al., 1999). Notch binding and activation
is regulated at multiple steps by molecules that control endocy-
tosis, O-fucosylation, and proteolytic cleavage, leading to the
release of the Notch intracellular domain (NICD) and its translo-
cation to the nucleus (De Strooper et al., 1999). After ligand acti-
vation, Notch signaling can be distinguished into canonical and
noncanonical pathways on the basis of whether NICD interacts
with a CBF1/RBPJ, Su(H), Lag-1 (CSL) transcription factor
(Kopan and Ilagan, 2009). In mice, the CSL factor is known as
recombination signal binding protein for immunoglobulin kappa
J region (RBPJk) and functions as a transcriptional repressor.
Canonical Notch signaling involves NICD binding to RBPJ and
converting it from a repressor to an activator, resulting in the
transcription of Notch-dependent genes which can influence
the developmental and differentiation programs (Davis and
Turner, 2001). Evidences of NICD binding to RBPJ maintaining
a repressor status have been recently reported and involve dislo-
cation and recruitment of coactivators and corepressors,
respectively (Sakano et al., 2010; Tiberi et al., 2012).
Although the precise mechanism(s) involved in the regulation
of hematopoiesis via the non-cell-autonomous Notch signaling
cascade remain unclear, recent studies have begun to shed
some insight into this process (Kim et al., 2008b; Yao et al.,
2011; Yoda et al., 2011, Klinakis et al., 2011). Although informa-
tive, the genetic models used in these studies involved deletion
of genes that affect global Notch signaling, both CSL-dependent
and -independent Notch signaling, and regulate other molecules
and effectors in addition to Notch (Pruessmeyer and Ludwig,
2009;De Strooper, 2005), thus preventing a clear understanding
of the specific downstream mechanisms.
In this study, we show that RBPJ functions as a transcriptional
repressor on the promoter of the microRNA miR-155. miR-155
is encoded from the B cell integration cluster locus and isCell Stem Cell 15, 51–65, July 3, 2014 ª2014 Elsevier Inc. 51
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of canonical Notch signaling induces direct upregulation of miR-
155 expression on BM stromal and endothelial cells and causes
significant alterations of hematopoiesis. Constitutive miR-155
upregulation due to loss of RBPJ transcriptional repression in-
duces nuclear factor kB (NF-kB) activation and a global state
of inflammation in the BM niche, leading to an uncontrolled
expansion of myeloid cells and the development of a myelopro-
liferative-like disease. Our results demonstrate a connection
between Notch signaling, miR-155, and NF-kB and suggest a
critical role for this pathway in maintaining hematopoietic
homeostasis and linking inflammation and cancer.
RESULTS
RBPJ Deletion in the BM Microenvironment Disrupts
Hematopoietic Homeostasis and Induces a
Non-Cell-Autonomous Myeloproliferative-like Disease
Inhibition of RBPJ transcriptional activity by deletion of its DNA
binding motif results in the complete loss of signaling via all
Notch receptors (Han et al., 2002). This RBPJ knockout model
has been successfully used to unveil the role of Notch in the
lymphoid compartment; however, the effects of RBPJ deletion
on myeloid cells were little investigated. RBPJ was condition-
ally deleted in the hematopoietic system by injecting mice
with pIpC, which induces Mx1-Cre expression in hematopoietic
(CD45+) as well as stromal (CD45) cells of the BM (Figures
S1A and S1B available online). Analysis of stem and progenitor
pools within the BM, spleen, and peripheral blood (PB) of mice
lacking RBPJ revealed a significant increase in the frequency
and absolute number of phenotypically defined primitive
Linc-Kit+Sca-1+ (LSK) cells, including long-term hemopoietic
stem cells (LT-HSCs), common myeloid progenitors (CMPs),
and granulocyte-macrophage progenitors (GMPs; Figures 1A
and 1D; Figures S1C–S1F). These increases were reflected
as expansion of immature myeloid (Gr1Mac1+) cells and neu-
trophils in the BM, spleen, and PB of RBPJ/ mice relative
to controls (Figures 1G–1H, left, and 7G). The numbers of
megakaryocyte-erythroid progenitors (MEPs), red blood cells
(RBCs), hemoglobin (Hb), hematocrit (HCT), and platelets
(PLTs) were reduced in mice lacking RBPJ (Figures S1G and
S1Q). RBPJ/ mice developed significant splenomegaly (Fig-
ure 1C), and histologic analysis confirmed myeloid expansion
in the BM, spleen, and myeloid cell infiltrates in liver and other
parenchymal organs. Overall, BM cellularity was significantly
increased (Figure S1H). Leukocyte counts and differentials
showed a progressive increase of myeloid cells in the PB of
RBPJ/ mice in comparison to controls: from 2-fold increase
at week 4 to 7-fold at week 20 after pIpC (Figures 1H and
S1N–S1O). As reported in a previous study (Han et al., 2002),
loss of Notch signaling in the lymphoid compartment was char-
acterized by reduction of T cells and relative expansion of B
cells (Figure S1P, left). Interestingly, B cells were increased in
the PB, but not in the BM and spleen, of RBPJ/ mice (data
not shown). RBPJ/ mice failed to live past 27 weeks and
died of a myeloproliferative-like disease (Figure 1I). In contrast,
mice haplo-insufficient for RBPJ, RBPJ+/, did not develop
disease, showing comparable survival to control animals up
to 40 weeks of followup.52 Cell Stem Cell 15, 51–65, July 3, 2014 ª2014 Elsevier Inc.To assess the relative contribution of cell-autonomous and
non-cell-autonomous mechanisms, we performed reciprocal
transplantation studies. BM cells from RBPJ+/+ and RBPJ/ ex-
pressing the CD45.2 allele were transplanted into wild-type (WT)
mice expressing the CD45.1 allele. Similar to the RBPJ/ mice,
theLSKpoolwassignificantly increased inWTmice reconstituted
with RBPJ/ donor cells in comparison to controls (Figure 1B,
left). However, there was no difference in the representation
of GMP, CMP, and MEP subsets in RBPJ/and RBPJ+/+ donor
populations (Figures 1E and S1I). Mice reconstituted with
RBPJ/ donor cells did not showmyeloid cell expansion and ex-
hibited normal levels of Gr1+Mac1+ neutrophils in the BM, spleen,
and PB (Figures 1G–1H, center). Thesemice did not display alter-
ations in RBCs, Hb, HCT, or PLTs (Figure S1Q) nor did they
developsplenomegaly,and their survivalwassimilar to thecontrol
cohort (Figure 1I). As previously reported,mice reconstitutedwith
RBPJ/ donor cells presented an overall decrease in T cells
accompanied by a relative increase in B cells (data not shown).
The leukocytedifferential count in the recipientsofRBPJ/donor
cells did not show neutrophilia or lymphocytosis (Figure S1N),
indicating that the effects observed in RBPJ/ mice were not
solely mediated by a cell-autonomous mechanism.
To examine the contribution of the microenvironment to the
myeloproliferative-like disease, we transplanted WT BM cells
into RBPJ/ or RBPJ+/+ recipients. Comparative analysis of he-
matopoietic subsets in the BM and spleen of RBPJ/ recipients
revealed that the loss of RBPJ in the BMmicroenvironment had a
lower impact on the LSK pool in RBPJ/ recipients (Figures 1B,
right, and S1J) than in parental RBPJ/mice or WT mice trans-
planted with RBPJ/ cells, demonstrating a cell-autonomous
contribution of RBPJ on HSC homeostasis. However, similar
to the RBPJ/ parental animals, RBPJ/ recipient mice trans-
planted with WT cells showed a significant increase in the fre-
quencies and absolute numbers of CMPs and GMPs in both
BM and spleen (Figures 1F and S1L). These changes were asso-
ciated with a marked decrease of MEPs, RBCs, Hb, and HCT
(Figures S1K and S1Q) and a significant increase in circulating
LSK cells (Figure S1J). RBPJ/ recipients showed a rapid and
progressive increase in neutrophils and Gr1+Mac1+ cells in the
PB, spleen, and BM (Figures 1G–1H, right) as well as increased
BM cellularity (Figure S1M). RBPJ/ recipients developed
marked splenomegaly (Figures 1C and 7D), hypercellular BM
with myeloid cell expansion, and myeloid infiltrates in the paren-
chymal organs (data not shown). A complete leukocyte count
and differential in the PB of RBPJ/ recipients indicated
a significant increase of myeloid cells (3-fold) in comparison to
RBPJ+/+ recipients, whereas lymphoid cells showed a kinetic
of engraftment similar to the controls and a relative decrease
in frequency in favor of myeloid cells (Figures S1N–S1P). Thus,
the loss of RBPJ in the microenvironment resulted in a lethal
myeloproliferative-like disease, which evolved rapidly after BM
transplant, as indicated by the shorter survival of RBPJ/ recip-
ients in comparison to RBPJ/ mice (100% of the mice were
dead by week 10; Figure 1I).
These data demonstrate that loss of RBPJ is not sufficient to
induce a cell-autonomous myeloid disease. Furthermore, they
clearly show that loss of RBPJ in themicroenvironment is neces-
sary and sufficient to induce a lethal myeloproliferative-like dis-
ease in a non-cell-autonomous manner.
Figure 1. Cell-Autonomous and Non-Cell-Autonomous Impact of RBPJ Deletion in the Hematopoietic Compartment
(A) Percentage of LSK cells in BM and spleen of RBPJ/ and RBPJ+/+ mice at 15–20 weeks after pIpC (n = 8–12).
(B) LSK cells in BM and spleen ofWT (CD45.1) recipient mice transplanted with CD45.2+RBPJ/ orRBPJ+/+BMdonor cells at 30 weeks posttransplant (left) and
RBPJ/ and RBPJ+/+ recipient mice transplanted with WT donor cells at 8 weeks after RBPJ deletion in the microenvironment (right). Results are expressed as
fold change of a percentage (n = 3–10).
(C) The bar graph summarizes average spleen weight from RBPJ/, RBPJ+/+, RBPJ/, and RBPJ+/+ recipient mice (n = 6–9).
(D) Percentage of CMPs and GMPs in BM and spleen of RBPJ/ and RBPJ+/+ mice (n = 8–12).
(E and F) Total CMP and GMP numbers per femur in WT (CD45.1) recipients transplanted with RBPJ/ or RBPJ+/+ BM cells 30 weeks posttransplant (n = 3–5; E)
or RBPJ/ and RBPJ+/+ recipients transplanted with WT CD45.1+ BM cells 6–8 weeks after pIpC (n = 6; F).
(G) Dot blots indicate Gr1 andMac1 expression in PB, spleen, and BM. Bar graphs summarize the percentage of Gr1+Mac1+ cells over whole population with data
from three independent experiments (n = 6–14).
(legend continued on next page)
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Figure 2. The RBPJ–/– BM Niche Favors
Myeloid Expansion and Trafficking
(A) Intravital imaging of mouse calvarium. RBPJ/
mice were induced with pIpC 4 weeks prior trans-
plantation of BM cells from Lys-EGFP donor mice.
Imaging was performed at 24 hr andweeks 2, 4, and 6
posttransplant. A series of 60 mm Z-stacks were
collected from six regions of calvarium BM in each
mouse. Images of one representative region of six at
weeks 2 and 6 in RBPJ/ and RBPJ+/+ recipients
(myeloid cells, green; vasculature, red). Cells
were detected automatically, and numbers were
computed in each region. The scale bar represents
50 mm.
(B) Upper graph, number of Lys-EGFP+ cells per re-
gion homed to BM at 24 hr; 32 ± 6 cells in RBPJ/
versus 31 ± 8 cells in RBPJ+/+ recipient mice (n = 12
regions; two independent experiments; p = nt sig-
nificant). Lower graph, kinetics of engraftment of Lys-
EGFP cells into RBPJ/ and RBPJ+/+ recipients over
time (mean ± SEM of cells in each region; n = 12–18
regions; two to three mice; *p = 0.019).
(C) Lys-EGFP expression on CMPs, GMPs, and LSK
cells at 2 weeks posttransplant in a representative
experiment. Values show the percentage of cells
expressing high levels of Lys-EGFP within each
specific subset (n = 2).
(D) Kinetics of neutrophil mobilization into PB in
RBPJ/ andRBPJ+/+ recipients after transplantation
of Lys-EGFP cells into RBPJ/ recipients (mean ±
SEM; n = 4–13; *p < 0.005).
(E) Spleen size inRBPJ/ recipients during time after
transplantation of Lys-EGFP cells (mean ± SD; n =
4–6; *p < 0.05; ***p < 0.005).
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Cell Expansion and Mobilization by Upregulating
Expression of G-CSF
Given that Mx1-Cre is expressed in the stromal cells of multiple
organs (Schneider et al., 2003), we questioned whether the
BM microenvironment was a critical site for disease initiation
in RBPJ/ mice. RBPJ/ and RBPJ+/+ littermates were trans-
planted with equal number of BM cells harvested from Lys-
EGFP reporter mice (wild-type RBPJ) in which EGFP expression
is driven by the lysozyme promoter (Faust et al., 2000). As lyso-
zyme expression is specific to myeloid cells (Miyamoto et al.,
2002), this strategy provided optimal visualization of the myeloid(H) Neutrophil counts in PB of RBPJ/ and RBPJ+/+ mice (left), WT recipients of RBPJ/ and RBPJ
recipients (right).
(I) Kaplan-Meyer survival curve of RBPJ/, RBPJ+/, and RBPJ+/+mice (n = 7–14; p < 0.01), WT mice rec
mice recipients of WT cells (n = 9–11; p < 0.01).
All results are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005 unless otherwise indicated.
See also Figure S1.
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croscopy. The BM niche was imaged at
24 hr and at weeks 2, 4, and 6 after trans-
plantation (Figure 2A). Homing at 24 hr
was similar in both conditions; however, by
week 2, Lys-EGFP cells transplanted in
RBPJ/ recipients had underwent a more
rapid and robust expansion then Lys-EGFP cells transplanted
in RBPJ+/+ mice (Figures 2A and 2B). At weeks 4 and 6 after
transplantation, the content of Lys-EGFP cells in the BM of
RBPJ/ recipients remained higher but not substantially
different from RBPJ+/+ recipients, as Lys-EGFP cells had also
expanded in the RBPJ+/+ recipients (Figure 2B). However, in
RBPJ/ recipients the Lys-EGFP cell expansion in the
BM was associated with a greater output of neutrophils and
Gr1+Mac1+ cells in the PB and progressive enlargement of the
spleen (Figures 2D and 2E). Significant increase in the proportion
of myeloid cells in the BM of RBPJ/ recipients was observed
again at advanced stages of disease (Figure 1G).+/+ donor cells (middle), and RBPJ/ and RBPJ+/+
ipients of RBPJ/ BM cells, and RBPJ/ or RBPJ+/+
Figure 3. The RBPJ–/– BM Niche Secrets
Increased Levels of G-CSF
(A) G-CSF levels (pg per ml) by ELISA in fresh BM
eluted from femurs of RBPJ/ or RBPJ+/+ re-
cipients 6 weeks after pIpC induction (n = 3).
(B) Serum G-CSF-levels (pg per ml) by ELISA in
RBPJ+/+, RBPJ+/, RBPJ/, and RBPJ/ recip-
ient mice 6 weeks after pIpC induction (n = 4).
(C) Percentage of Gr1+Mac1+ cells in PB of
RBPJ/ and RBPJ+/+ mice treated with anti-G-
CSF neutralizing Ab or vehicle control (n = 3).
(D) Spleens from RBPJ+/+ and RBPJ/ mice
treated with G-CSF Ab or vehicle control; repre-
sentative experiment (n = 3).
(E) Percentage of CMP (left) and GMP subsets
(right) in spleen of RBPJ/ and RBPJ+/+ mice
treated with anti-G-CSF Ab or vehicle control
(n = 3).
(F and G) RBPJ (F) and Notch target gene Hes1 (G)
expression by qRT-PCR in BM stroma from
RBPJ/ or RBPJ+/+ mice (n = 3).
(H) G-CSF and TNFa levels by cytokine array in
BM-derived stroma supernatant from RBPJ/ and
RBPJ+/+ mice. Results are expressed as pixel
density (n = 3).
(I) Left, number of WT Lin progenitors from 48 hr
coculture on BM stroma from RBPJ/ or RBPJ+/+
mice (n = 7). Right, acquisition of myeloid markers
by Lin progenitor cells. Results are expressed as a
percentage of Gr1+Mac1+ cells (n = 4; p = 0.09).
All results are expressed as mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.005 unless otherwise indicated.
See also Figure S2.
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to mature neutrophils, allowing measurement of the kinetics of
differentiation by fluorescent intensity. As expected, Lys-EGFP
expression was low in LSK cells in both groups, whereas anal-
ysis of CMPs and GMPs revealed a higher number of high Lys-
EGFP-expressing cells in RBPJ/ recipients than in RBPJ+/+
recipients, suggesting a more rapid rate of myeloid cell differen-
tiation (Figure 2C). These data indicate that the RBPJ/ BM
microenvironment is a primary site of myeloid cell expansion,
which is accompanied by rapid differentiation and mobilization
of myeloid cells in the PB and spleen.
Analysis of serum cytokines by cytokine arrays revealed a
significant increase in the levels of several inflammatory cyto-
kines in RBPJ/mice (Figure S2A), in particular G-CSF, a driver
of myeloid cell proliferation and differentiation. Increased G-CSF
levels were confirmed in the BM milieu and in the serum of
RBPJ/ mice by ELISA (Figures 3A and 3B). HeterozygousCell Stem Cell 15RBPJ+/ mice, which did not develop dis-
ease, displayed G-CSF levels just above
the baseline of normal mice. To deter-
mine the contribution of G-CSF to the
myeloproliferative-like disease, we treated
RBPJ/mice with G-CSF neutralizing an-
tibodies (Abs). Anti-G-CSF treatment re-
sulted in the normalization of Gr1+Mac1+
cells in the PB (Figure 3C), a significant
reduction in the spleen size (Figure 3D), anotable decrease in the proportion of CMPs, and a significant
reduction in level of GMPs (Figure 3E). These data suggest
that G-CSF is a major, but not the sole, contributor to the myelo-
proliferative-like disease occurring in RBPJ/ mice. TNFa
levels were also consistently elevated in the absence of RBPJ
(Figures S2A–S2C), suggesting that TNFa, a cytokine involved
in myeloid progenitor homeostasis (Walkley et al., 2007), may
play a synergistic role with G-CSF in promoting myeloid cell
expansion.
Analysis of cytokines in the supernatant of RBPJ/ BM-der-
ived stromal cells, validated for loss of RBPJ and Notch signaling
(Figures 3F and 3G), demonstrated a proinflammatory profile
similar to the one observed in the serum (Figure S2B). These ex-
periments confirmed a significant increase in the levels of G-CSF
and TNFa in RBPJ/ stromal cells (Figure 3H). Accordingly,
RBPJ/ BM-derived stromal cells showed a greater ability
to support myeloid cell expansion and differentiation of BM, 51–65, July 3, 2014 ª2014 Elsevier Inc. 55
Figure 4. Contribution of the RBPJ–/– BM
Endothelial Niche to the Myeloid Expansion
(A–C)RBPJ (A),G-CSF (B), and TNFa (C) transcript
levels by qRT-PCR in sorted CD45CD105+C31
(MSC) and CD45CD105+C31+ (EC) cells from BM
of RBPJ+/+ or RBPJ/ mice. Fold change is
shown (n = 3).
(D and E) Neutrophil counts (D) and percentage of
Gr1+Mac1+ (E) cells in PB.
(F and G) Percentage of Gr1+Mac1+ cells (F) and
CMPs and GMPs (G) in spleens of Tie2RBPJ/
and Tie2RBPJ+/+mice at 6 months after tamoxifen
induction in comparison to Mx-RBPJ/ mice
induced with pIpC (n = 6–7).
(H) Spleens from Tie2RBPJ/ and Tie2RBPJ+/+
mice in representative experiment. The bar graph
shows spleen weights (n = 6–7).
(I) G-CSF and TNFa levels (pg per ml) by ELISA
in serum of Tie2RBPJ/ and Tie2RBPJ+/+ mice
6 months after tamoxifen induction (n = 6–7).
All results are expressed as mean ± SEM; *p <
0.05, **p < 0.01, ***p < 0.005. See also Figure S3.
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These results demonstrate that RBPJ deletion in the BM stro-
mal cells induces proinflammatory cytokines, generating a
BM niche exceedingly favorable to myeloid progenitor cell
expansion.
Contribution of RBPJ–/– BM Endothelial Cells to the
Myeloproliferative-like Disease
Next, we sought to determine which specific stromal cell type(s)
in the BM were responsible for the increased cytokine produc-
tion in RBPJ-deficient mice. Coculture experiments of Lin
progenitor cells with RBPJ/-derived osteoblasts (OBs) or
characterization of hematopoiesis in mice with RBPJ deletion
in osteocytes did not show impact on the myeloid compartment,
ruling out a major role of mature bone cells in the myeloid expan-
sion (Figures S3A–S3E). In contrast, sorted BM CD45CD105+
CD31 cells (enriched in mesenchymal like-cells; BM MSCs)
and BM CD45CD105+CD31+ VE-cadherin+ cells (enriched in
endothelial cells; BM ECs) demonstrated higher levels of G-56 Cell Stem Cell 15, 51–65, July 3, 2014 ª2014 Elsevier Inc.CSF and TNFa in association with RBPJ
deletion (Figures 4A–4C). Given the
significantly higher expression of G-CSF
and TNFa in BM ECs of RBPJ/ mice
and the known role these cells play in
producing proinflammatory cytokines,
we sought to further investigate the role
of the BM endothelial niche. To this
end, we crossed RBPJ/ mice with the
tamoxifen-inducible Tie2CreER mice. In
these mice, the Cre recombinase is
expressed under the control of the Tie2
promoter in which specific regulatory
elements were modified to restrict the
expression of Cre to ECs, with negligible
expression in the hematopoietic system
(Forde et al., 2002). Tamoxifen-induced
Tie2CreER+/RBPJlox/lox and Tie2CreER/
RBPJlox/lox mice (referred as Tie2RBPJ/ and Tie2RBPJ+/+
mice) were analyzed at 6 months postinduction. In these mice,
the average reduction of RBPJ on sorted BM EC was approxi-
mately 30%. Despite the incomplete deletion of EC RBPJ, anal-
ysis of the hematopoietic compartment of Tie2RBPJ/ mice
demonstrated a significant increase in neutrophils and Gr1+/
Mac1+ cells in the PB (Figures 4D and 4E), increased Gr1+/
Mac1+, CMP and GMP cells in the spleen (Figures 4F and 4G)
and splenomegaly (Figure 4H) compared to Tie2RBPJ+/+
mice. These changes were associated with increased levels of
G-CSF and TNFa in Tie2RBPJ/ mice serum (Figure 4I). All pa-
rameters of myeloid cell expansion were similarly increased in
Tie2RBPJ/ mice as those observed in Mx1RBPJ/ mice
(i.e., CMPs and GMPs; Figure 4G); however, these changes
occurred less rapidly in the Tie2RBPJ/ background. Thus,
deletion of RBPJ in ECs is sufficient to induce myeloid cell
expansion. However, the contribution of other stromal cell types,
including MSCs, may be important for the development of a
full-blown and rapid myeloproliferative-like disease.
Figure 5. RBPJ Functions as Repressor on
miR-155 Promoter
(A and B)miR-155 levels by qRT-PCR in BM stroma
cells from RBPJ+/+ or RBPJ/ mice (n = 4; A)
and BM sorted CD45CD105+C31 (MSC) or
CD45CD105+C31+ (BM EC) cells from RBPJ+/+,
RBPJ/ mice (n = 3; B). CD45CD105+C31+ cells
(n = 6) include also BM cells sorted from
Tie2Cre+RBPJ/ and Tie2CreRBPJ+/+ mice.
Fold change is shown.
(C and D) RBPJ (C) and miR-155 (D) transcripts
levels by qRT-PCR in ECs treated with shRBPJ.
Fold change is shown (mean ± SD; n = 2–3).
(E and F) RBPJ (E) and miR-155 (F) transcripts
levels by qRT-PCR in Raw cells treated with
shRBPJ. Fold change is shown (n = 3).
(G) Scheme of the RBPJ binding sites in the pre-
miR-155/BIC promoter.
(H) ChIP assay of total BM from RBPJ/ or
RBPJ+/+ mice and ECs and Raw cells transfected
with shRBPJ or scrambled shRNA. IP was con-
ductedwith no Ab, an irrelevant Ab, or Abs directed
to RBPJ followed by PCR of themiR-155 promoter.
Three independent experiments were performed
for each.
(I) miR-155 luciferase assay. Raw cells expressing
the shRBPJ or treatedwith HDAC inhibitor (1 mM) or
with GSI (1 mM) were transfected with the miR-155
promoter region containing the RBPJ binding
sites. Results are expressed as fold change in
relative light units (RLU; n = 4; two independent
experiments).
All results are expressed asmean ± SEM; *p < 0.05,
**p < 0.01, ***p < 0.005. See also Figure S4.
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Upregulation of miR-155
The coordinated upregulation of multiple inflammatory cytokines
upon deletion of RBPJ suggests the involvement of master reg-
ulators triggering a proinflammatory circuitry. Likely candidates
for such function are microRNAs. Analysis of the expression
of several microRNAs implicated in inflammation showed a sig-
nificant increase in the expression of miR-155 in RBPJ/ BM
stromal cells (Figure 5A). No significant changes in the expres-
sion of miR-196b, miR-210, miR-125a, and miR-146a were
noted under similar conditions (Figure S4A). Increased expres-
sion of miR-155 in RBPJ/ stroma was validated with BM
sorted populations enriched in MSCs and ECs as well as ECs
derived from Tie2RBPJ/mice (Figure 5B). miR-155 expression
was also upregulated in Lin RBPJ/ hematopoietic cells, but
not in bulk CD45+ cells (Figures S4B and S5D). To determine
the molecular link between RBPJ and miR-155 in vitro, murine
microvascular ECs and BM stromal cell lines Raw264.7 (Raw)Cell Stem Cell 15,and OP9 were transfected with small
hairpin RNAS (shRNAs) directed toward
RBPJ (shRBPJ; Figure S4C). Expression
of the shRBPJ upregulated miR-155
expression in ECs, Raw cells, and in OP9
cell lines (Figures 5C–5F, S4D, and S4E).
The upregulated miR-155 was functional,
as shown by the target luciferase assay(Figure S4F). Given that RBPJ is a transcriptional repressor, we
hypothesized that RBPJ associates with the miR-155 promoter
and suppresses its transcription. In silico analysis of the BIC/
miR-155 promoter revealed the presence of two putative RBPJ
binding sites (Jarriault et al., 1995) at 1,792 and at 1,703 nt
upstream of the start site (Figure 5G). Chromatin immunoprecip-
itation (ChIP) analysis of the promoter with primers (Table S1) for
these two regions confirmed binding of endogenous RBPJ to the
endogenous miR-155 promoter in cells derived from RBPJ+/+
mice but not RBPJ/ mice (Figure 5H, left). Similarly, binding
of RBPJ to miR-155 promoter was observed in ECs and Raw
cells and was abrogated after shRBPJ transfection (Figure 5H,
middle and right). Notch was also found in the complex when
RBPJ was present (Figure S4G). Furthermore, to confirm the
repressor activity of RBPJ on the miR-155 promoter, we cloned
the 2 kb pre-miR-155 promoter region containing the two RBPJ
binding sites into a luciferase reporter construct. Consistent with
a repressor function of RBPJ, miR-155 transcriptional activation51–65, July 3, 2014 ª2014 Elsevier Inc. 57
Figure 6. Inhibition of kB-Ras1 by miR-155 Upregulates G-CSF and TNFa via NF-kB
(A andB) ECs (A) andRaw cells (B) transfectedwith shRBPJ or scrambled shRNA (sc) were analyzed forG-CSF and TNFa expression by qRT-PCR. Fold change is
shown (n = 3–5).
(C) Total number WT BM Lin progenitors cocultured for 48 hr with Raw cells transduced with shRBPJ or scrambled shRNA (n = 4–6).
(D) G-CSF and TNFa transcript levels by qRT-PCR in Raw cells transduced with MSCV/GFP or MSCV-miR-155/GFP. Fold change is shown (n = 5).
(legend continued on next page)
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ure 5I). miR-155 expression was also increased after treatment
of Raw cells with the g-secretase inhibitor (GSI; Figure 5I), which
inhibits the generation of NICD and ultimately prevents the for-
mation of the NICD/RBPJ complex on the promoter. Conversely,
overexpression of NICD decreased miR-155 expression in Raw
cells and in T cells (Figures S4H and S4I). Given that RBPJ has
been shown to associate with the histone deacetylase complex
(HDAC) (Kao et al., 1998) and HDAC2 binding is observed at the
miR-155 promoter in WT Raw cells (Figure S4J), we investigated
whether RBPJ regulated miR-155 repression through HDAC
function. Treatment with a pan HDAC inhibitor led to a 3-fold in-
crease in the expression of miR-155 similar to the effect induced
by deletion of RBPJ (Figure 5I).
miR-155 Induces G-CSF and TNFa Expression via NF-kB
Activation
Given the strong correlation between miR-155 upregulation and
increased G-CSF and TNFa levels, we hypothesized that miR-
155 regulates G-CSF and TNFa production by BM stromal cells.
Transfection of shRBPJ in ECs and Raw cells resulted in
increased G-CSF and TNFa expression and protein levels (Fig-
ures 6A–6B and S5A) and enhanced their ability to promote
myeloid cell expansion in coculture (Figure 6C). Similarly, over-
expression of miR-155 in Raw cells resulted in rapid upregulation
ofG-CSF and TNFa (Figure 6D). Consistently, treatment ofRBPJ
knocked down cells with an anti-miR-155 LNA inhibited
shRBPJ-mediated induction of G-CSF and TNFa (Figures 6E
and S5B). Thus, loss of RBPJ augments G-CSF and TNFa levels
by directly upregulating the expression of miR-155.
To identify the molecular link between miR-155 and inflamma-
tory cytokines,weused themicroRNA target predictionsprogram
(https://cm.jefferson.edu/rna22v1.0-mus_musculus/) (Miranda
et al., 2006) and searched for putative miR-155 targets whose in-
hibitionmight result in the transcriptional activation ofG-CSF and
TNFa. Among the predicted targets, the NF-kB inhibitor kB-Ras1
(also known as Nkiras1) that inhibits IkB-b phosphorylation (Fen-
wick et al., 2000) was found to havemiR-155 target sequences at
its 30 untranslated region (30 UTR). Given that the inflammatory
profile observed in RBPJ/ stromal cells has a NF-kB signature
(Figure S2) and that the transcription ofG-CSF and TNFa is regu-
lated principally byNF-kB,we tested the hypothesis thatmiR-155
upregulation increased NF-kB activation by decreasing its inhibi-(E)G-CSF transcript levels by qRT-PCR in Raw cells transfectedwith shRBPJ and
Representative experiments express fold change.
(F) kB-Ras1 transcript levels by qRT-PCR in BM stroma cells from RBPJ+/+ or RB
(G) kB-Ras1 transcript levels in raw cells transfected with shRBPJ and or scram
(miR155). Fold change is shown (n = 4–6).
(H) kB-Ras1 transcript levels in raw cell controls (Co) or cells transduced with MS
miR-155 (n = 3–6) are shown.
(I) kB-Ras1 30 UTR Luciferase assay in Raw cells transduced with MSCV/GFP or
(J) kB-Ras1 transcript levels by qRT-PCR in Raw cells and ECs transfected with
(K) Raw cells and ECs transfected with shkB-Ras1 or scrambled shRNA were an
(right) in ECs transfected with shkB-Ras1 or scrambled shRNA. Fold change is s
(L) NF-kB Luciferase assay in Raw cells transfected with shRBPJ and or scramble
change RLU is shown (n = 4–6).
(M) G-CSF and TNFa transcripts by qRT-PCR in Raw cells transfected with shR
inhibitor DAMPT. Fold change is shown (n = 3).
All results are expressed as mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.005. Seetion. kB-Ras1 protein levels were noticeably reduced in RBPJ/
mice (Figure S5C), and kB-Ras1 expression was significantly
decreased in RBPJ/ BM stroma (Figure 6F). In Raw cells, kB-
Ras1 expression was significantly reduced by repressing RBPJ
or overexpressing miR-155 (Figure 6G). Importantly, kB-Ras1
downregulation in these cells was antagonized by miR-155
locked nucleic acid (LNA; Figure 6H). Next, we cloned the
kB-Ras1 30 UTR into the pMIR-RL vector and confirmed that
kB-Ras1 is a bona fide miR-155 target, as shown by decreased
luciferase activity in response to miR-155 overexpression (Fig-
ure 6I). Targeting of kB-Ras1 by shRNA (shkB-Ras1) increased
expression of G-CSF and TNFa in both Raw cells and ECs
(Figures 6J and 6K). kB-Ras1 inhibition correlated with increased
transcriptional activation of NF-kB in Raw shRBPJ and Raw
MSCV-miR155-expressing cells (Figure 6L), and inhibition of
NF-kB by the NF-kB inhibitor dimethylamino-parthenolide
(DMAPT) (Neelakantan et al., 2009) resulted in a significant
decrease in the expression of G-CSF and TNFa (Figure 6M).
Finally, analysis of miR-155, kB-Ras1, G-CSF, and TNFa expres-
sion showed that sorted BM ECs and MSCs from RBPJ/ mice
had thehighest expressionofmiR-155, correlatingwith the lowest
expression of kB-Ras1 and higher levels of G-CSF and TNFa
in comparison to purified osteoblasts and sorted CD45+ cells
(Figure S5D).
Altogether, our results demonstrate that, after Notch/RBPJ
loss of function, miR-155 upregulates NF-kB activation by tar-
geting one of its inhibitors, kB-Ras1, leading to increased
expression of G-CSF and TNFa. Furthermore, these results sug-
gest that this axis may be cell-context-dependent and likely to
be more active in BM ECs and MSCs.
miR-155 Is Required for the Development of RBPJ-
Dependent Myeloproliferative-like Disease and Is
Upregulated in the BM of MPN Patients
To examine the impact of miR-155 deletion on RBPJ dependent
myeloproliferative neoplasia (MPN) development, we generated
Mx1RBPJlox/lox/miR-155/ (DKO) and Mx1RBPJlox/lox/miR-
155+/+ (KO) littermates. Consistent with our previous results,
deletion of RBPJ induced a lethal myeloproliferative-like dis-
ease, and KO mice died within 20 weeks of pIpC treatment. In
contrast, all DKO mice remained viable at this same time point.
Comparative analysis of the hematopoietic compartment in
these mice showed that neutrophils increased dramatically inor scrambled shRNA in the presence of 75 nM LNA control or LNA anti-miR155.
PJ/ mice. Fold change is shown (n = 4).
bled shRNA (sc) or transduced with MSCV/GFP (Co) or MSCV-miR-155/GFP
CV-miR-155/GFP (miR155) in the presence of 75 nM LNA control or LNA anti-
MSCV-miR-155/GFP. Fold change RLU is shown (n = 3).
shkB-Ras1 or scrambled shRNA. Fold change is shown (n = 3–4).
alyzed for G-CSF and TNFa expression by qRT-PCR. NF-kB Luciferase assay
hown (n = 3–4).
d shRNA (sc) or transduced with MSCV/GFP (Co) or MSCV-miR155/GFP. Fold
BPJ or scrambled shRNA (sc) in culture for 24 hr with or without 5 mM NF-kB
also Figure S5.
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Figure 7. Loss of miR-155 Rescues the RBPJ–/– Phenotype
(A) Neutrophil counts in PB of RBPJ+/+miR-155+/+, RBPJ/miR-155+/+ (KO), and RBPJ/miR-155/ (DKO) mice up to 16 weeks from pIpC induction (n = 3-8).
(B) Percentage of BM CMP and GMP subsets in the Lin population of KO and DKO mice at 20 weeks after induction (mean ± SD; n = 3–8).
(C–E) KO and DKO were induced with pIpC and after 2 weeks were transplanted with WT BM cells. At week 10 posttransplant, when the level of engraftment
was > 90%, data were collected.
(C) Percentage of Gr1+Mac1+ in PB (mean ± SD; n = 3–7).
(D) Representative spleens. The bar graph indicates spleen weight (n = 3–6).
(E) Percentage of CMPs and GMPs in the BM (mean ± SD; n = 3–8).
(legend continued on next page)
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PB neutrophils (Figure 7A), lacked the development of spleno-
megaly (Figure S6A), and showed only a modest increase in
CMPs and GMPs in the BM in comparison to KO mice (Fig-
ure 7B). Importantly, G-CSF levels in the serum of DKO recipi-
ents were similar to those seen in healthy controls (Figure S6B).
To prove that miR-155 knockdown in the stroma is critical for
myeloid cell expansion, we transplantedWTBMcells into lethally
irradiatedDKOandKOmice.Asanticipated,KO recipientsdevel-
oped disease, whereas deletion of miR-155 in the stroma of DKO
recipients correlated with only a modest increase in Gr1+Mac1+
cells in the PB (Figure 7C), and prevented the development of
splenomegaly and the increase of myeloid progenitors (CMPs
and GMPs) in the BM (Figures 7D and 7E). Histologic analysis
of the DKO recipients showed absence of themyeloid expansion
with normalmyeloid/erythroid ratio in the BMand intact structure
of the spleen (Figure 7G). A significant decrease of kB-Ras1
expression was observed in sorted KO BM ECs and MSCs in
comparison to WT cells (Figure S5D). Conversely, the levels of
kB-Ras1 were increased or restored to normal in sorted DKO
BM ECs and MSCs in comparison to KO cells (Figure 7F). The
normalization of kB-Ras1 expression in DKO cells correlated
with the normalization of G-CSF and TNFa expression.
Altogether, these experiments show a key role for miR-155
in sustaining the inflammatory reaction driving the lethal myelo-
proliferative-like disease triggered by the loss of RBPJ. To
determine the potential clinical relevance of our observations,
we examined whether miR-155 was also altered in patients
with MPN characterized by a high inflammatory component,
such as myelofibrosis (MF). Analysis of 85 MF patients revealed
a significant increase in the expression of miR-155 in total BM
cells in comparison to normal control patients (Figure 7H),
whereas an increase was not detected in mononuclear cells of
the PB (data not shown). Collectively, this observation suggests
that miR-155may play a role in the human disease and represent
a potential therapeutic target for the control of myeloid cell
expansion.
DISCUSSION
Evidence supporting a non-cell-autonomous role for Notch
signaling in the regulation of hematopoiesis has recently
emerged; however, the cellular and molecular mechanism(s) by
which Notch regulates the integrity of the BM niche are still
poorly understood. By using a Notch/RBPJ loss-of-function
model we demonstrated that RBPJ functions as a transcriptional
repressor of the microRNA miR-155: a microRNA involved in
inflammation and frequently upregulated in leukemia cells and
solid tumors. miR-155 upregulation due to loss of the Notch/
RBPJ axis increased NF-kB activation by targeted inhibition of
kB-Ras1 and induced a persistent proinflammatory state of the
BM niche leading to a myeloproliferative-like disease.(F) kB-Ras1,G-CSF, and TNFa expression by qRT-PCR in sorted BMCD45+, ECs
(G) Wright and Gimsa staining of BM cytospins and histological (H&E) analyses
spleen represents 500 mm.
(H) miR-155 expression by qRT-PCR in MPN patients. The dot scatter plot indic
matched healthy donors.
All results are expressed as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005 unleGlobal (canonical and noncanonical) loss of Notch signaling
due to deletion of Mindbomb (Kim et al., 2008b), ADAM10
(Yoda et al., 2011), or Pofut1 (Yao et al., 2011) has been corre-
latedwith the development of amyeloproliferative-like syndrome
driven by both cell-autonomous and non-cell-autonomous
mechanisms, whereas deletion of Nicastrin has been shown to
lead instead to a cell-autonomous chronic-myelomonocytic-leu-
kemia-like disease (Klinakis et al., 2011). Discrepancies among
these models may be due to the contribution of other targets
regulated by ADAM10 (Pruessmeyer and Ludwig, 2009), Pofut1,
and the Nicastrin g-secretase complex (De Strooper, 2005),
which, acting in combination with global Notch loss of function,
may account for the variable involvement of the microenviron-
ment. However, the molecular mechanisms linking loss of Notch
signaling with altered myelopoiesis were not defined in these
models.
Our study clearly shows that loss of RBPJ, a nonredundant
downstream effector of canonical Notch signaling, is necessary
and sufficient to induce a lethal myeloproliferative-like disease
driven by the microenvironment. RBPJ/ stem and progenitor
cells were not capable of inducing myeloid expansion or a
myeloproliferative disease in a cell-autonomous manner. This
effect was further confirmed with the Lys-CreRBPJlox/lox model,
in which the RBPJ deletion occurs only in the myeloid progeni-
tors starting at the CMP stage (Figures S3F and S3G). Notably,
our studies clearly uncouple the direct, cell-autonomous role of
Notch/RBPJ signaling on HSC homeostasis from its non-cell-
autonomous impact on myeloid progenitors. Interestingly,
lymphocytosis was observed only in the parental RBPJ/
mice and not in the BM chimeras, suggesting that this process
requires both cell-autonomous and non-cell-autonomousmech-
anisms. Additional studies are warranted in order to understand
the impact of RBPJ loss on this process.
Here, we unveil a link between RBPJ-dependent Notch
signaling and miR-155. RBPJ represses transcription by binding
to specific sequence motifs in the promoter of target genes and
by recruiting corepressors such as SMRT and SHARP (Oswald
et al., 2005) and the HDAC complex (Kao et al., 1998). Our study
shows that RBPJ binds to the miR-155 promoter and that either
deletion of RBPJDNA binding domain or loss of full-length RBPJ
causes miR-155 upregulation. Importantly, our data show that
RBPJ-mediated repression ofmiR-155 is NICD-dependent, sug-
gesting the possibility that Notch may also function as a tran-
scriptional repressor. This is intriguing considering that it is well
established that NICD converts RBPJ from a transcriptional
repressor to a transcriptional activator (Kopan and Ilagan,
2009). However, precedents of Notch signaling as repressor
have been reported and involve dislocation and recruitment of
coactivators and corepressors, respectively (Sakano et al.,
2010; Tiberi et al., 2012). Alternatively, it is possible that the as-
sociation of NICD to RBPJ, which can enhance its binding to a
specific promoter (Krejcı´ and Bray, 2007; Castel et al., 2013),, MSCs, and cultured OBs from RBPJ/ and DKOmice. Fold change (n = 3–6).
of spleen. The scale bar for BM cytospin represents 20 mm. The scale bar for
ates relative expression of miR-155 in the BM of 85 MF patients and ten age-
ss otherwise indicated. See also Figure S6.
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however, whether the presence of NICD on the miR-155 pro-
moter enhances RBPJ repressor activity directly or indirectly
needs to be further investigated. Collectively, these data support
the possibility that miR-155 expression may be physiologically
regulated by tuning of the Notch signaling and may indicate a
more general mechanism of miR-155 regulation through repres-
sion. This hypothesis is supported by a recent study reporting in-
hibition of miR-155 by transcriptional repression in breast cancer
cells, where mutations in the tumor suppressor BRCA1 gene
abolishes its repressive function on the miR-155 promoter, re-
sulting in increased miR-155 expression in breast cancer cells
and in tumor progression (Chang et al., 2011).
miR-155 plays a broad role in inflammation and the regulation
of the immune system, and it is induced by a wide range of in-
flammatory factors, including LPS and TLR responses. Although
increased expression of miR-155 has been positively associated
with increased cytokine production, in particular G-CSF and
TNFa (Tili et al., 2009; Worm et al., 2009), the molecular mecha-
nism(s) by which miR-155 enhances the expression of these
cytokines were not investigated. Our results show that miR-
155 increases NF-kB activation by targeting one of its negative
regulators, kB-Ras1 (Fenwick et al., 2000). kB-Ras1 (also known
as Nkiras1) is a small protein with similarity to Ras-like small
GTPases that functions as a negative modulator of NF-kB by
binding to NF-kB/IkB complexes and preventing IkBb and IkBa
phosphorylation by IKK (Chen et al., 2004). kB-Ras1 is ubiqui-
tously expressed, and its levels inversely correlate with poor
prognosis in tumors. Although prior studies have suggested an
important role for NF-kB in regulating miR-155 expression (Bal-
timore et al., 2008), our findings reveal that miR-155 can recipro-
cally upregulate NF-kB activity and amplify the inflammatory
response by inducing NF-kB-dependent cytokines, in particular
G-CSF and TNFa.
A previous report demonstrated a cell-intrinsic role for
miR-155 in driving myeloproliferative-like disease in a murine
transduction/transplantation model (O’Connell et al., 2008).
Our findings clearly demonstrate a non-cell-autonomous mech-
anism by which miR-155 overexpression contributes to a myelo-
proliferative-like disease in RBPJ-deficient mice. Interestingly,
although RBPJ/ progenitors exhibit miR-155 upregulation,
transplantation of these cells in WT recipients did not lead to a
myeloid expansion. This discrepancy ismost likely due to the dif-
ferential expression of miR-155 in the two murine models as well
as differences in the cell types producing this microRNA. As dis-
cussed by Tili et al. (2009), the differential impact of miR-155 on
its targets can depend significantly on the level of its expression.
Thus, in contrast to models of forced expression, resulting in a
30-fold increase of miR-155 on hematopoietic cells in compar-
ison to normal levels (O’Connell et al., 2008), the miR-155 levels
reached in our model (3- to 5-fold increase) were likely not
enough to drive a cell-autonomous MPN but were sufficient to
drive cytokine production in cells of the BM microenvironment
specialized to generate an inflammatory response, such as
endothelial cells. Our studies point to cell context differences
and a higher ability of BM ECs and MSCs to activate
the miR-155/NF-kB/G-CSF/TNFa pathway in comparison to
hematopoietic cells and osteoblasts. Indeed, we show that
RBPJ deletion in endothelial cells is sufficient to drive a myelo-62 Cell Stem Cell 15, 51–65, July 3, 2014 ª2014 Elsevier Inc.proliferative-like disease. A relevant role of ECs in this process
is not surprising, given that stem cells and progenitors localize
adjacent to sinusoids in the BM and that ECs are poised to regu-
late the hematopoietic response during inflammation through
production of proinflammatory cytokines (Ding et al., 2012;
Fernandez et al., 2008).
Both G-CSF and TNFa are commonly upregulated upon TLR-
mediated stimulation during emergency granulopoiesis and after
infections (Hirai et al., 2006; Ueda et al., 2005). Their increased
expression is also a common feature of several animal models
of myeloproliferative-like disease (Dumortier et al., 2010; Fulzele
et al., 2013; Walkley et al., 2007; Yoda et al., 2011) and it is
observed in patients with MPN (Tefferi et al., 2011). Our discov-
ery of the Notch/miR-155/NF-kB/cytokines axis suggests the
hypothesis that Notch signalingmay contribute to hematopoietic
homeostasis by regulating the level of the inflammatory state in
the BM niche. In support of this idea, a recent report noted phys-
iologic downregulation of Notch signaling in response to LPS
(Kim et al., 2008a); furthermore, epigenetic silencing of Notch
in myeloid malignancies has been documented (Lobry et al.,
2013). Thus, while transitory inhibition of Notch signaling in the
BM microenvironment may trigger a physiologic inflammatory
circuit characterized by miR-155/NF-kB/cytokine induction
driving myeloid cell expansion in response to BM stress (such
as infection or acute inflammation), continuous inhibition of
Notch signaling due to persistence of inflammatory feedback
loops, and/or epigenetic mechanisms may contribute to the
development or progression of a myeloproliferative disorder.
Consistent with our observations demonstrating an essential
role for Notch/RBPJ in regulating miR-155 and driving a myelo-
proliferative-like disease in a murine model, we observed a sig-
nificant overexpression of miR-155 in MF patient BM samples
(enriched in stromal cellular components) but not in the PB. Rele-
vant to these findings is the notion that NF-kB plays an essential
role in multiple myeloid malignancies and that a comprehensive
cytokine profile on serum derived from MF patients demon-
strated a cytokine profile very similar to that observed in our
mouse model of RBPJ deficiency (Tefferi et al., 2011). Collec-
tively, these findings provide a strong link between miR-155/
NF-kB and MPN and the rationale to explore this molecular
axis to target inflammation and disease progression in these
diseases.
EXPERIMENTAL PROCEDURES
Mice
RBPJlox/lox mice were obtained from T. Honjo, Tie2CreER mice were obtained
from B. Arnold (European Mouse Mutant Archive), miR-155/ and Lys-Cre
mice were obtained from the Jackson Laboratories, Lys-EGFP mice were
obtained from T. Graf, and DMP1Cre/RBPJ/ mice were obtained from
T. Bellido.Mx1-Cre recombinasewas induced by pIpC 200 mg intraperitoneally
(i.p.) injected three times at a 2-day interval (week 1) plus one single dose
(week 2). Efficiency of RBPJ excision was assessed by quantitative RT-PCR
(qRT-PCR; primers are listed in Table S1), and Tie2CreER expression was
induced by tamoxifen 100 mg/kg body for 4–5 weeks twice daily by gavage.
Animal experiments were performed with protocols approved by the Indiana
University School of Medicine Animal Care and Use Committee.
Cells and Cell Culture
Raw264.7 and OP9 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) and a-MEM with 10% fetal bovine serum (FBS) at 37C.
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pLKO.1 vector or with psiLvU6-shkB-Ras1 or control vector (GeneCopoeia)
with Lipofectamine 2000 reagent (Life Technologies) or the retroviral vectors
MSCV-GFP, MSCV-ICN/GFP, or MGP M155 (MSCV-miR-155, Addgene).
BM stromal cells were generated from long bones (tibias and femurs) prein-
cubated with 1% collagenase. Total BM cells were flushed and cultured in
a-MEM with 20% FBS. Nonadherent cells were removed after 2 days of cul-
ture, and adherent cells were expanded for 1 week prior sorting in order to pu-
rify CD45 BM stromal cells by CD45 microbeads (Miltenyi Biotec).
Mouse lung microvascular endothelial cells (Kuhlencordt et al., 2004) were
provided by I. Petrache. Cells were grown in DMEM with 20% FBS. Osteo-
blasts were obtained by long bones as described previously (Chitteti et al.,
2010).
For cocultures, Lin cells were purified from femur BM with the lineage cell
depletion kit (Miltenyi Biotec), plated at a density of 5 3 104 per ml on a
confluent BM stromal cell layer, and cultured for 48 hr in Iscove’smodified Dul-
becco’s medium (GIBCO, Invitrogen) containing 10% FBS, 50 ng/ml stem cell
factor, and 20 ng/ml IL-3 (Miltenyi Biotec). Raw cells were treated with 1 mM
GSI (EMD, Calbiochem), 1 mM HDAC inhibitor (Vorinostat), or 5 mM DMAPT
(provided by P. Crooks) for 24 or 48 hr. For LNA treatment, cells were trans-
fected with 75 nM LNA scramble or anti-miR-155 (Exiqon) with Lipofectamine
2000 (Invitrogen). Cells were collected for analysis at days 2 and 4
posttransfection.
Patient Cells
Primary patient BM aspirates were obtained from MPN patients with MF seen
at the University of Texas MD Anderson Cancer Center, and normal BM cells
samples were obtained from STEMCELL Technologies. BM cells were frac-
tionated with Ficoll Hypaque 1077 (Sigma-Aldrich).
Flow Cytometry and Cell Sorting
BM, spleen, and PB cell suspensions were labeled with monoclonal Abs used
to define distinct hematopoietic subsets (Table S2). Cells were acquired on an
LSRII (BD Biosciences), and events (0.5 to 53 106 per staining) were collected
and analyzed with FlowJo. CD45CD31+CD105+ and CD45CD31–CD105+
cells were sorted on the Reflection3 cell sorter from total BM cells after staining
with CD45-APC, CD31-FITC, and CD105-PE.
BM Transplantation
Total BM cells (5 3 106) from pIpC-induced Mx-Cre+ RBPJlox/lox or control
Mx-Cre littermates (CD45.2) were transplanted by tail-vein injection into
lethally irradiated B6-SJL (CD45.1) recipients. Total BM cells (3 3 106) from
CD45.1WT or Lys-EGFPmice were transplanted into irradiated, pIpC-induced
Mx-Cre+ RBPJlox/lox or control Mx-Cre recipient mice. For histology, tissues
were fixed in Z-fix buffer, embedded with paraffin, sectioned, and stained
with hematoxylin and eosin.
G-CSF Ab In Vivo
Mx1-Cre+ andMx1-Cre RBPJlox/lox 6- to 8-week-old mice were induced with
pIpC and, after 6 weeks, treated with anti-G-CSF neutralizing Ab (R&D Sys-
tems) 10 mg per day i.p. for two cycles of 12 days.
Cytokine Array and ELISA
BMmilieu was obtained by flashing one femur with 1ml of MILLIPLEX reagent.
Serumwas collected fromPB, and BM-stroma supernatants at 72 hr collection
were used. Cytokine levels were measured with a mouse cytokine array (R&D)
and Luminex MAP assays (MILLIPLEX MAP Mouse Cytokine/Chemokine,
Millipore).
qRT-PCR and MicroRNA Quantification
RNAwas purified with the RNeasy Mini Kit (QIAGEN), and cDNA was prepared
with the Superscript II Kit (Invitrogen). qRT-PCR was performed with SYBR
green II Brilliant (Stratagene), and primers are shown in Table S1.
Total RNA from BM sorted cells, BM-derived stroma, and Raw cells were
extracted with RNAqueous Micro Kit (Ambion). MicroRNA expression was
assessed by qRT-PCR (Applied Biosystems) with microRNA-specific TaqMan
MicroRNA Assays (mmu-miR-155, U6snRNA). BM from healthy donors and
PMF patients was extracted with Trizol (Invitrogen), and 10 ng of total RNAfrom each sample was transcribed with the TaqMan MicroRNA reverse Tran-
scriptase Kit on an ABI 7900HT FAST platform (Applied Biosystems). miR-155
and control gene RUN6B (Applied Biosystems) expression were analyzed by
qRT-PCR with TaqMan probes.
Cloning of miR-155 Promoter, kB-Ras1 30 UTR, Gene Reporter
Assay, and ChIP Analysis
The mouse miR-155 promoter region (1,842 to 18) containing the RBPJ
binding sites was amplified by PCR from C57BL/6 mouse spleen genomic
DNA (primers are listed in Table S1). Cloning was performed into the site be-
tween XhoI and HindIII of the pGL4.10 luciferase reporter vector (Promega)
and confirmed by sequencing. A Dual-Luciferase Assay (Promega) was per-
formed in order to quantify miR-155 promoter activity. Raw cells were cotrans-
fected with pGL4.10/miR-155Luc and the CMV/Renilla luc control plasmid.
The mouse kB-Ras1 30 UTR region (+779 to +4,592) containing two miR155
binding sites was amplified by PCR from C57BL/6 mouse genomic DNA
(primers are listed in Table S1). Cloning was performed into the site between
SacI and PmeI of the pmiR-RL vector. Raw cells were cotransfected with
the pmiR-RL vector and the CMV/Renilla luc control plasmid in order to deter-
mine targeting of the kB-Ras1 30 UTR by miR155. miR-155 levels and function
were also measured in cells by cotransfecting a firefly luciferase reporter con-
taining a binding site for miR-155 at 30 UTR downstream of the luciferase gene
(Signosis) and the control Renilla plasmid. Luminescence was measured 24 to
48 hr after transfection with a TD-20/20 luminometer (Turner Biosystems).
Chromatin preparations from RBPJ/ and RBPJ+/+ BM or Raw cells trans-
fected with shRBPJ or scrambled shRNA were crosslinked with endogenous
DNA and immunoprecipitated with anti-RBPJ (Santa Cruz Biotechnology,
28713) (Barbarulo et al., 2011), anti-Notch1 (Santa Cruz, 6014-R), and anti-
HDAC2(Cell Signaling Technology, 2545S). As negative controls, IgG or irrele-
vant Abs (anti-Jagged1; Santa Cruz, 8303) were used, and anti-PolII was used
as positive control. Recovered DNA was analyzed for miR-155 and GAPDH
(control) promoter fragments by qRT-PCR with specific primers (Table S1).
Imaging Acquisition and Image Analysis
Two-photon images of calvariumBMwere collectedwithOlympus XLUMPLFL
20xW, NA 0.95 objective. Z-stacks were collected through the depth of tissue
(60 mm Z-stacks) from six regions of calvarium BM at a step size of 1 mm and a
frame size of 512 3 512 pixels. Projection images were created with Meta-
Morph (Molecular Devices). The volume-rendering software Voxx was used
to create 3D reconstructions of BM.
Statistical Analysis
Equality of distributions for matched pairs of observations was tested with
a Student’s t test. Survival was calculated with Kaplan-Meier calculations.
p < 0.05 was considered to be statistically significant.
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